Abstract:
A compound medicine for treating acute and chronic hepatitis B, includes a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex, which has functions of directly killing HBV and destroying replication template of HBV. Auxiliary formulas thereof include high-purity oxymatrine and glycyrrhizin sulfate. The oxymatrine has an effect of anti-HBV, and is capable of treating acute and chronic hepatitis B, regulating immune system and increasing leukocyte. Serving as a main hepatocyte membrane protective agent, the glycyrrhizin sulfate has not only an effect of anti-inflammation, but also it is capable of regulating immune system and protecting hepatocyte. The compound medicine has no toxicity or side effect.

Description:
CROSS REFERENCE OF RELATED APPLICATION 
       [0001]    This is a Continuation-In-Parts application of an application having an application number PCT/CN2013/078719, filed Jul. 3, 2013, which claims priority under 35 U.S.C. 119(a-d) to CN  201310147738 . 6 , filed Apr. 25, 2013. 
     
    
     BACKGROUND OF THE PRESENT INVENTION 
       [0002]    1. Field of Invention 
         [0003]    The present invention relates to a medicine for treating hepatitis B, and particularly to a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex targeting hepatitis B virus. 
         [0004]    2. Description of Related Arts 
         [0005]    Hepatitis B virus (HBV) is a species of genus Orthohepadnavirus causing acute or chronic hepatitis B of human beings. The hepatitis B is a disease caused by HBV. Currently, there is no medicine capable of completely curing hepatitis B. Only a few medicines are capable of assisting patients in fighting against and inhibiting HBV to control their symptoms. Currently, only a small kind of medicine is capable of targeting hepatitis B virus and the treatment effect thereof is far from satisfactory. 
       SUMMARY OF THE PRESENT INVENTION 
       [0006]    An object of the present invention is to provide a complex capable of targeting hepatitis B virus, comprising a principal component of alkali metal ion and selenium coordination complex, and supplementary components of glycyrrhizin sulfate and oxymatrine. 
         [0007]    Another object of the present invention is to provide an organic selenium compound with therapeutic effects on hepatitis B. 
         [0008]    Accordingly, in order to attain the above objects, the present invention provides a complex targeting hepatitis B virus, comprising a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex which has a basic structure of an aromatic ring, wherein: 
         [0009]    the aromatic ring comprises at least two functional groups, each of which is one member selected from the group consisting of oxygen functional group, sulphur functional group, phosphorus functional group and nitrogen functional group; and a selenium coordination complex functional group is formed by selenium, alkali metal ion and the mentioned functional groups. 
         [0010]    Beneficial effects of the present invention are described as follows. The polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex of the present invention has characteristics of over 20% selenium content and no toxicity, and has revolutionary effects in killing virus, enhancing human immunity and etc. 
         [0011]    These and other objectives, features, and advantages of the present invention will become apparent from the following detailed description, the attached illustrations, and the appended claims. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0012]      FIG. 1  is a high performance liquid chromatography diagram of a complex targeting hepatitis B virus according to a preferred embodiment of the present invention. 
           [0013]      FIG. 2  is illustrations of  FIG. 1 . 
       
    
    
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT 
       [0014]    According to a preferred embodiment of the present invention, a complex targeting hepatitis B virus comprising a principal component of a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex, and supplementary components of glycyrrhizin sulfate and oxymatrine, 
         [0015]    wherein a basic structure of the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex has an aromatic ring, wherein the aromatic ring comprises at least two functional groups, each of which is one member selected from the group consisting of oxygen functional group, sulphur functional group, phosphorus functional group and nitrogenfunctional group; and selenium coordination complex functional group is formed by selenium, alkali metal ion and the mentioned functional groups. 
         [0016]    According to a preferred embodiment of the present invention, a preparing method of the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex comprises following steps of: 
         [0017]    a) hydrolyzing lignin to obtain multiple-structural polyphenolic compounds; 
         [0018]    b) reacting the multiple-structural polyphenolic compounds with at least one kind of inorganic metal base to obtain multivalent phenolic hydroxyl carboxylate; and 
         [0019]    c) reacting the multivalent phenolic hydroxyl carboxylate with SeO 2  to obtain multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts, wherein the multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts are the organic selenium composition. 
         [0020]    According to another preferred embodiment of the present invention, the complex targeting hepatitis B virus further comprises oxymatrine and glycyrrhizin sulfate. 
         [0021]    Preferably, a purity of the oxymatrine ≧95%, a purity of the glycyrrhizin sulfate ≧98%, a mass fraction of the oxymatrine has a range of 15˜50%, a mass fraction of the glycyrrhizin sulfate has a range of 10˜50%, and a mass fraction of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex has a range of 5˜40%.
       1. The oxymatrine has direct function of anti-HBV.   2. The oxymatrine is capable of inhibiting activity of collagen and preventing fibrosis of liver.   3. The oxymatrine is capable of blocking abnormal apoptosis of liver cells.   4. The oxymatrine has a protective effect on liver failure of experimental mice.   5. The oxymatrine is capable of treating chronic hepatitis.   6. The oxymatrine is capable of regulating the function of immunity and increasing the amount of leukocyte in virtue of its anti-inflammatory and antiallergenic properties.   7. The glycyrrhizin sulfate is capable of protecting membrane structure of liver cells.   8. The glycyrrhizin sulfate has effects of anti-HBV and preventing allergic reactions caused by the HBV.   9. The glycyrrhizin sulfate is capable of improving hepatic function.       
 
         [0031]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein the oxygen functional group comprises: hydroxyl, carboxylic group, phenolic group, quinonyl, quinonyl and hydroxyl, alcoholic hydroxyl, phenolic hydroxyl, sulfonic group, amino group, free quinonyl, semiquinone, quinonic oxygen group, monomethyl, and at least one kind monomethyl-active functional group which comprises methoxyl, carboxymethyl, hydroxymethyl, phenolic methyl and methylamino group. 
         [0032]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex comprises the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0033]    wherein M is alkali metal ion. 
         [0034]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex comprises the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0035]    wherein R═CH 3 .CH 2 CH 2 CH 3 . 
         [0036]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex comprises the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0037]    wherein R is a functional segment of alkali metal ion and selenium coordination complex. 
         [0038]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein R has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0039]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein R has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0040]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein R has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0041]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein R has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0042]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein R has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0043]    wherein M is alkali metal ion, X is N, S or P. 
         [0044]    According to a preferred embodiment of the present invention, the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is illustrated, wherein its molecular weight thereof is 100˜600. 
         [0045]    According to a preferred embodiment of the present invention, aqueous solution of the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is weakly alkaline, pH thereof is 7.2˜8.5, water-solubility thereof is high, and lipophilicity thereof is good. 
         [0046]    According to a preferred embodiment of the present invention, a preparing process of the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex comprises following steps of: 
         [0047]    1. obtaining one kind of multiple-structural polyphenolic compound by means of biotechnological hydrolysis, wherein the multiple-structural polyphenolic compound is weakly acidic (pH: 4.5˜6.5), and has good water-solubility, wherein: 
         [0048]    molecules of the multiple-structural polyphenolic compound have aromatic rings or other heterocycles such aspyrrole, furan, indole and etc.; the aromatic rings are connected by bridge bond; the aromatic rings may have a variety of active functional groups comprising: hydroxyl, carboxylic group, phenolic group, phenolic hydroxyl, quinonyl, quinonyl and hydroxyl, alcoholic hydroxyl, sulfonic group, amino group, free quinonyl, semiquinone, quinonic oxygen group, monomethyl, and at least one kind monomethyl-active functional group which comprises methoxyl, carboxymethyl, hydroxymethyl, phenolic methyl and methylamino group; 
         [0049]    2. reacting the multiple-structural polyphenolic compound with at least one kind of inorganic alkali metal to obtain low-aromaticity multivalent phenolic hydroxyl carboxylate, which is polymeric, nonhomogeneous, alkaline (pH: 10˜12), has high solubility and is capable of dissolving into multiple solvents; 
         [0050]    3. reacting the multivalent phenolic hydroxyl carboxylate with SeO 2  to obtain low-aromaticity multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts, wherein a functional group thereof is alkali metal ion and selenium coordination complex, aqueous solution thereof is weakly alkaline (pH: 7.2˜8.0), water solubility thereof is high, and lipophilicity thereof is good; 
         [0051]    wherein the multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts consist of a plurality of polyphenolic structures with functional fragments of alkali metal ion and selenium coordination complex. 
         [0052]    Fundamental structure of the polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is bigeminal or poly-phenolic hydroxyl, methoxyl, carboxylic group, quinonyl and hydroxyl and etc. 
         [0053]    The polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex is newly produced compound. 
         [0054]    Principle of the present invention is as follows. Taking advantage of isosteric principle, N, S or P in functional groups of the multiple-structural polyphenolic compounds is replaced by Se, or N, S or P in the functional groups of the multiple-structural polyphenolic compounds is connected with Se by covalent bond to form the alkali metal ion and selenium coordination complex. 
         [0055]    The alkali metal ion forms bidentate or multidentate coordinate bond with O, S, N or P, and O also forms bidentate or multidentate coordinate bond with Se. 
       Example 1 
       [0056]    A polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0057]    wherein M is alkali metal ion. 
         [0058]    In this example, the structure 
         [0000]    
       
                 
         
             
             
         
       
     
         [0059]    is capable of serving as a functional group 
         [0060]    R in other structures. 
         [0061]    In this example, a preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex comprises following steps of: 
         [0062]    a) adding 2.0% urea into lignosulfonate-water solution containing 20% solid formation for serving as growth medium (pH=6.0), wherein the lignosulfonate-water solution is extracted from depickling paper pulp by sulphuric acid; inoculating the growth medium with 2% mixed strains comprising:  candida tropicalis, pseudomonas, candida utilis  and strains of effective microorganisms from Japan, and fermenting for 72 hours under a temperature of 30° C. to obtain the multiple-structuralpolyphenolic compounds, wherein an inoculation proportion thereof is 1:2:2:2; and
       b) reacting the multiple-structural polyphenolic compounds with sodium hydroxide to obtain multivalent phenolic hydroxyl sodium carboxylate, wherein multiple-structural polyphenolic compounds: sodium hydroxide=1:1˜0.1, wherein a reaction temperature thereof is 120° C., and materials are mechanically stirred to be uniformly mixed while reacting; and   c) reacting the multivalent phenolic hydroxyl sodium carboxylate with SeO 2  to obtain multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts, wherein the multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts are organic selenium composition, multivalent phenolic hydroxyl sodium carboxylate: SeO 2 =1:1˜0.1, a reaction temperature thereof is 150° C., and materials are mechanically stirred to be uniformly mixed while reacting.       
 
         [0065]    Moreover, other various structures of compounds of the present invention are also obtained by means of the above mentioned preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex. 
         [0066]    The above produced polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is mixed with oxymatrine and glycyrrhizin sulfate and then dried, in such a manner that the complex targeting hepatitis B virus of the present invention is obtained. 
       Example 2 
       [0067]    A polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0068]    wherein R═CH 3 .CH 2 CH 2 CH 3 . 
         [0069]    In this example, a preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex comprises following steps of: 
         [0070]    a) adding 2.0% urea into lignosulfonate-water solution containing 20% solid formation for serving as growth medium (pH=6.0), wherein the lignosulfonate-water solution are extracted from depickling paper pulp by sulphuricacid; inoculating the growth medium with 2% mixed strains comprising:  candida tropicalis, pseudomonas, candida utilis  and strains of effective microorganisms from Japan, and fermenting for 72 hours under a temperature of 30° C. to obtain the multiple-structural polyphenolic compounds, wherein an inoculation proportion thereof is 1:2:2:2; and
       b) reacting the multiple-structural polyphenolic compounds with potassium hydroxide to obtain multivalent phenolic hydroxyl potassium carboxylate, wherein multiple-structural polyphenolic compounds: potassium hydroxide=1:1˜0.1, wherein a reaction temperature thereof is 120° C., and materials are mechanically stirred to be uniformly mixed while reacting; and   c) reacting the multivalent phenolic hydroxyl potassium carboxylate with SeO 2  to obtain multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts, wherein the multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts are organic selenium composition, multivalent phenolic hydroxyl potassium carboxylate: SeO 2 =1:1˜0.1, a reaction temperature thereof is 140° C., and materials are mechanically stirred to be uniformly mixed while reacting.       
 
         [0073]    Moreover, other various structures of compounds of the present invention are also obtained by means of the above mentioned preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex. 
         [0074]    The above produced polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is mixed with oxymatrine and glycyrrhizin sulfate and then dried, in such a manner that the complex targeting hepatitis B virus of the present invention is obtained. 
       Example 3 
       [0075]    A polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex has the following structure of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0076]    wherein R is a functional fragment of alkali metal ion and selenium coordination complex. 
         [0077]    In this example, a preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex comprises following steps of: 
         [0078]    a) adding 2.0% urea into lignosulfonate-water solution containing 20% solid formation for serving as growth medium (pH=6.0), wherein the lignosulfonate-water solution are extracted from depickling paper pulp by sulphuric acid; inoculating the growth medium with 2% mixed strains comprising:  candida tropicalis, pseudomonas, candida utilis  and strains of effective microorganisms from Japan, and fermenting for 72 hours under a temperature of 30° C. to obtain the multiple-structural polyphenolic compounds, wherein an inoculation proportion thereof is 1:2:2:2; and
       b) reacting the multiple-structural polyphenolic compounds with at least one kind of inorganic metal base such as NaOH or KOH to obtain multivalent phenolic hydroxyl sodium carboxylate or multivalent phenolic hydroxyl potassium carboxylate, etc.; and   c) reacting the multivalent phenolic hydroxyl sodium/potassium carboxylate and etc. with SeO 2  to obtain multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts comprising Na or K or other alkali metal, wherein the multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts are organic selenium composition, multivalent phenolic hydroxyl carboxylic acid selenium coordination complex salts comprising alkali metal: SeO 2 =1:1˜0.1, a reaction temperature thereof is 140° C., and materials are mechanically stirred to be uniformly mixed while reacting.       
 
         [0081]    Moreover, other various structures of compounds of the present invention are also obtained by means of the above mentioned preparing process of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex. 
         [0082]    The above produced polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex is mixed with oxymatrine and glycyrrhizin sulfate and then dried, in such a manner that the complex targeting hepatitis B virus of the present invention is obtained. 
         [0083]    After taking the complex targeting hepatitis B virus obtained according to a preferred embodiment of the present invention, following volunteers all achieve effective therapeutic results. 
         [0000]    
       
         
               
             
               
               
               
               
             
           
               
                   
               
               
                 Therapeutic Effects of the Medicine on Volunteers 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 Volunteer 1 
                 Sex: male 
                 Age: 62 
               
               
                   
                   
               
             
          
         
       
     
         [0084]    The volunteer takes 0.4 g solid capsule of the complex targeting hepatitis B virus twice daily, morning and evening, wherein the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex is prepared according to the preferred embodiment 1 of the present invention, a purity of the oxymatrine is 95%, a mass fraction of the oxymatrine is 40%, a purity of the glycyrrhizin sulfate is 98%, a mass fraction of the glycyrrhizin sulfate is 40%, and a mass fraction of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex is 20%. 
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Medical Examination Result Prior to the Medicine Administration 
               
               
                 May 11, 2012 
               
             
          
           
               
                 Code of item 
                 Name of item 
                 Result 
                 Reference value 
                 Unit 
               
               
                   
               
               
                 HBV-DNA 
                 DNA of HBV 
                 4.48E+06 
                 &lt;1.0*10{circumflex over ( )}3 
                 copies/ml 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Medical Examination Result Posterior to the Medicine Administration 
               
               
                 Sep. 10, 2012 
               
             
          
           
               
                   
                   
                   
                   
                 Minimum 
               
               
                   
                   
                   
                   
                 detection 
               
               
                 Code of item 
                 Name of item 
                 Result 
                 Unit 
                 limit 
               
               
                   
               
               
                 HBV-DNA 
                 DNA of HBV 
                 Less than minimum 
                 IU/ml 
                 5.00E{circumflex over ( )}2 
               
               
                   
                   
                 detection limit 
               
               
                   
               
             
          
         
       
     
       Medical Diagnostics Prior to the Medicine Administration 
       [0085]    The maximum value of fasting blood glucose is 19.3, and the value of 2-hour postprandial blood glucose reaches 35.4. The volunteer carries hepatitis B virus. 
         [0086]    Symptoms prior to the medicine administration: myasthenia of limbs, dry mouth, thirsty, frequent micturition, hunger, sweating due to debility, marasmus and insomnia. After therapy with insulin at hospital, the blood glucose has become normal. The volunteer takes entecavir for treating hepatitis. 
         [0087]    Self-description by the volunteer is as follows. Appetite, defecation, sleep, stamina and emotion are all in normal condition. The volunteer 1 feels good, his limbs are powerful, his motion is normal. The volunteer 1 plays ping-pong every day. The past abnormal symptoms disappear, no abnormal feelings now. 
         [0088]    Onset time of curative effect: 20 days posterior to the medicine administration, it took effect. After continuous administration of the medicine for 50 days, the patient is cured. 
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Medical Examination Result Posterior to Drug Withdrawal for 3 Months 
               
               
                 Dec. 24, 2012 
               
             
          
           
               
                   
                   
                   
                   
                 Minimum 
               
               
                   
                   
                   
                   
                 detection 
               
               
                 Code of item 
                 Name of item 
                 Result 
                 Unit 
                 limit 
               
               
                   
               
               
                 HBV-DNA 
                 DNA of HBV 
                 Less than minimum 
                 IU/ml 
                 5.00E{circumflex over ( )}2 
               
               
                   
                   
                 detection limit 
               
               
                   
               
               
                 Volunteer 2 Sex: male Age: 41 Medical record: hepatitis B cirrhosis 
               
             
          
         
       
     
         [0089]    The volunteer takes 0.4 g solid capsule of the complex targeting hepatitis B virus twice daily, morning and evening, wherein the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex is prepared according to the preferred embodiment 1 of the present invention, a purity of the oxymatrine is 95%, a mass fraction of the oxymatrine is 40%, a purity of the glycyrrhizin sulfate is 98%, a mass fraction of the glycyrrhizin sulfate is 40%, and a mass fraction of the polyphenolic selenium compound having the functional group of alkali metal ion and selenium coordination complex is 20%. 
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Medical Examination Result Prior to the Medicine Administration 
               
               
                 Jan. 11, 2013 
               
             
          
           
               
                 Item name 
                 Item for short 
                 Result 
                 Unit 
                 Reference value 
               
               
                   
               
               
                 Hepatitis B virus DNA 
                 HBV-DNA 
                 9.36 × 10{circumflex over ( )}2 
                 IU/ml 
                 &lt;40 
               
               
                 quantity 
               
               
                 Total protein 
                 TP 
                 83    
                 g/L 
                 60~83 
               
               
                 Albumin 
                 ALB 
                 46    
                 g/L 
                 35~55 
               
               
                 Globulin 
                 GLO 
                 36    
                 g/L 
               
               
                 Ratio of albumin to globulin 
                 A/G 
                 1.28 
               
               
                 Prealbumin 
                 PAL 
                 142↓      
                 mg/L 
                 160~400 
               
               
                 Direct bilirubin 
                 DBIL 
                 19.2↑ 
                 umol/L 
                     0~6.8 
               
               
                 Total bilirubin 
                 TBIL 
                 41.7↑ 
                 umol/L 
                  3.4~20.5 
               
               
                 Ratio of direct to total 
                 D/T 
                 0.46 
               
               
                 bilirubin 
               
               
                 Alanine aminotransferase 
                 ALT 
                 404↑      
                 U/L 
                  5~40 
               
               
                 Aspartate aminotransferase 
                 AST 
                 270↑      
                 U/L 
                  8~40 
               
               
                 Ratio of AST/ALT 
                 S/T 
                 0.67 
               
               
                 Alkaline phosphatase 
                 ALP 
                 138    
                 U/L 
                  40~150 
               
               
                 R-glutamyl transpeptidase 
                 GGT 
                 88↑      
                 U/L 
                 11~50 
               
               
                 Total bile acid 
                 TBA 
                 26↑      
                 umol/L 
                  0~10 
               
               
                 Cholinesterase 
                 CHE 
                 5998     
                 U/L 
                  5400~13200 
               
               
                 Lactate dehydrogenase 
                 LDH 
                 221    
                 U/L 
                 109~245 
               
               
                 5′-ribonuclease 
                 5NT 
                 6   
                 U/L 
                  0~10 
               
               
                 Adenosine deaminase 
                 ADA 
                 51↑      
                 U/L 
                  0~20 
               
               
                 Urea 
                 UREA 
                 4.6  
                 mmol/L 
                 2.9~8.2 
               
               
                 Creatinine 
                 CRE 
                 87    
                 umol/L 
                  62~115 
               
               
                 Uric acid 
                 UA 
                 317    
                 umol/L 
                 208~428 
               
               
                 Alpha-fetoprotein 
                 AFP 
                 14    
                 ng/ml 
                  0~20 
               
               
                 Leukocyte 
                 WBC 
                 5.01 
                 10{circumflex over ( )}9/L 
                  4~10 
               
               
                 Leutrophils percentage 
                 NE % 
                  0.637 
                   
                 0.5~0.7 
               
               
                 Absolute neutrophil count 
                 NE# 
                 3.2  
                 10{circumflex over ( )}9/L 
                 2~7 
               
               
                 Lymphocyte percentage 
                 LY % 
                  0.201 
                   
                 0.2~0.4 
               
               
                 Absolute lymphocyte count 
                 LY# 
                 1.01 
                 10{circumflex over ( )}9/L 
                 0.8~4.0 
               
               
                 Monocytes percentage 
                 M0 % 
                  0.087 
                   
                 0.03~0.1  
               
               
                 Absolute monocytes count 
                 M0# 
                 0.43 
                 10{circumflex over ( )}9/L 
                 0.12~1.0  
               
               
                 Eosinophils percentage 
                 E0 % 
                   0.069↑ 
                   
                 0.005~0.05  
               
               
                 Absolute eosinophils count 
                 E0 
                 0.35 
                 10{circumflex over ( )}9/L 
                 0.02~0.5  
               
               
                 Basophil percentage 
                 BA % 
                  0.006 
                   
                   0~0.01 
               
               
                 Absolute basophil count 
                 BA# 
                 0.03 
                 10{circumflex over ( )}9/L 
                     0~0.1 
               
               
                 Erythrocyte 
                 RBC 
                 4.95 
                 10{circumflex over ( )}12/L 
                     4~5.5 
               
               
                 Hemoglobin 
                 HGB 
                 161.00  
                 g/L 
                 131~172 
               
               
                 Hematocrit 
                 HCT 
                 48.10  
                 % 
                     38~50.8 
               
               
                 Mean corpuscular volume 
                   
                 97.2  
                 fL 
                 82.6~99.1 
               
               
                 Corpuscular hemoglobin 
                   
                 336    
                 g/L 
                 320~362 
               
               
                 concentration 
               
               
                 Mean corpuscular 
                   
                 32.6  
                 pg 
                 26.9~33.8 
               
               
                 hemoglobin 
               
               
                 Erythrocyte hemoglobin 
                   
                 14.6  
                 % 
                  0~15 
               
               
                 distribution width 
               
               
                 Platelet 
                 PLT 
                 102.00  
                 10{circumflex over ( )}9/L 
                 100~300 
               
               
                 Thrombocytocrit 
                   
                  0.099 
                   
                 0.06~0.40 
               
               
                 Mean platelet volume 
                   
                 9.7  
                 fL 
                 7.54~11.2 
               
               
                 Platelet distribution width 
                 PDW 
                 11.2  
                 % 
                  9.0~18.0 
               
               
                 Platelet large cell ratio 
                 P-LCR 
                 24.5  
                 % 
                 13~43 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Medical Examination Result Posterior to the Medicine Administration for One Month 
               
               
                 Testing method: fluorescent quantitative nucleic acid testing 
               
               
                 Testing time: Feb. 8, 2013 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 Name of item 
                 Item 
                 Result 
                 Unit 
                 Reference value 
               
               
                   
               
               
                 Fluorescent quantitative nucleic 
                 HBV-DNA 
                 1.14 × 10{circumflex over ( )}2 
                 IU/ml 
                 &lt;40 
               
               
                 acid testing HBV 
               
               
                   
               
               
                 Item name 
                 Item for short 
                 Result 
                 Unit 
                 Reference value 
               
               
                   
               
               
                 Total protein 
                 TP 
                 76    
                 g/L 
                 60~83 
               
               
                 Albumin 
                 ALB 
                 45    
                 g/L 
                 35~55 
               
               
                 Globulin 
                 GLO 
                 32    
                 g/L 
               
               
                 Ratio of albumin to globulin 
                 A/G 
                 1.42 
               
               
                 prealbumin 
                 PAL 
                 159↓      
                 mg/L 
                 160~400 
               
               
                 Direct bilirubin 
                 DBIL 
                  9.6↑ 
                 umol/L 
                 0~6.8 
               
               
                 Total bilirubin 
                 TBIL 
                 20.1↑ 
                 umol/L 
                 3.4~20.5 
               
               
                 Ratio of direct to total 
                 D/T 
                 0.48 
               
               
                 bilirubin 
               
               
                 Alanine aminotransferase 
                 ALT 
                 58↑      
                 U/L 
                 5~40 
               
               
                 Aspartate aminotransferase 
                 AST 
                 44↑      
                 U/L 
                 8~40 
               
               
                 Ratio of AST/ALT 
                 S/T 
                 0.80 
               
               
                 Alkaline phosphatase 
                 ALP 
                 114       
                 U/L 
                 40~150 
               
               
                 r-glutamyl transpeptidase 
                 GGT 
                 44↑      
                 U/L 
                 11~50 
               
               
                 Total bile acid 
                 TBA 
                 30↑      
                 umol/L 
                 0~10 
               
               
                 Cholinesterase 
                 CHE 
                 6752     
                 U/L 
                 5400~13200 
               
               
                 Lactate dehydrogenase 
                 LDH 
                 157    
                 U/L 
                 109~245 
               
               
                 5′-ribonuclease 
                 5NT 
                 3   
                 U/L 
                 0~10 
               
               
                 Adenosine deaminase 
                 ADA 
                 37↑      
                 U/L 
                 0~20 
               
               
                 Urea 
                 UREA 
                 3.6  
                 mmol/L 
                 2.9~8.2 
               
               
                 Creatinine 
                 CRE 
                 91    
                 umol/L 
                 62~115 
               
               
                 Uric acid 
                 UA 
                 360    
                 umol/L 
                 208~428 
               
               
                 Leukocyte 
                 WBC 
                 4.85 
                 10{circumflex over ( )}9/L 
                 4~10 
               
               
                 Leutrophils percentage 
                 NE % 
                  0.611 
                   
                 0.5~0.7 
               
               
                 Absolute neutrophil count 
                 NE# 
                 3.0  
                 10{circumflex over ( )}9/L 
                 2~7 
               
               
                 Lymphocyte percentage 
                 LY % 
                  0.244 
                   
                 0.2~0.4 
               
               
                 Absolute Lymphocyte count 
                 LY# 
                 1.18 
                 10{circumflex over ( )}9/L 
                 0.8~4.0 
               
               
                 Monocytes percentage 
                 M0 % 
                  0.091 
                   
                 0.03~0.1 
               
               
                 Absolute monocytes count 
                 M0# 
                 0.45 
                 10{circumflex over ( )}9/L 
                 0.12~1.0 
               
               
                 Eosinophils percentage 
                 E0 % 
                  0.050 
                   
                 0.005~0.05 
               
               
                 Absolute eosinophils count 
                 E0 
                 0.24 
                 10{circumflex over ( )}9/L 
                 0.02~0.5 
               
               
                 Basophil percentage 
                 BA % 
                  0.004 
                   
                 0~0.01 
               
               
                 Absolute basophil count 
                 BA# 
                 0.02 
                 10{circumflex over ( )}9/L 
                 0~0.1 
               
               
                 Erythrocyte 
                 RBC 
                 4.89 
                 10{circumflex over ( )}12/L 
                 4~5.5 
               
               
                 Hemoglobin 
                 HGB 
                 160.00  
                 g/L 
                 131~172 
               
               
                 Hematocrit 
                 HCT 
                 47.20  
                 % 
                 38~50.8 
               
               
                 Mean corpuscular volume 
                   
                 96.6  
                 fL 
                 82.6~99.1 
               
               
                 Corpuscular hemoglobin 
                   
                 339    
                 g/L 
                 320~362 
               
               
                 concentration 
               
               
                 Mean corpuscular 
                   
                 32.8  
                 pg 
                 26.9~33.8 
               
               
                 hemoglobin 
               
               
                 Erythrocyte hemoglobin 
                   
                 14.3  
                 % 
                 0~15 
               
               
                 distribution width 
               
               
                 Platelet 
                 PLT 
                  94.00↓ 
                 10{circumflex over ( )}9/L 
                 100~300 
               
               
                 Thrombocytocrit 
                   
                  0.088 
                   
                 0.06~0.40 
               
               
                 Mean platelet volume 
                   
                 9.3  
                 fL 
                 7.54~11.2 
               
               
                 Platelet distribution width 
                 PDW 
                 11.0  
                 % 
                 9.0~18.0 
               
               
                 Platelet large cell ratio 
                 P-LCR 
                 21.5  
                 % 
                 13~43 
               
               
                   
               
             
          
         
       
     
         [0090]    Onset time of curative effect: after a continuous medicine administration for one month, copies of HBV decreased by nearly 90%. 
         [0091]    One skilled in the art will understand that the embodiment of the present invention as shown in the illustrations and described above is exemplary only and not intended to be limited. 
         [0092]    It will thus be seen that the objects of the present invention have been fully and effectively accomplished. Its embodiments have been shown and described for the purposes of illustrating the functional and structural principles of the present invention and are subject to change without departure from such principles. Therefore, this invention includes all modifications encompassed within the spirit and scope of the following claims.